Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $2.5700 (1.58%) ($2.3200 - $2.6700) on Thu. Feb. 24, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.49% (three month average) | RSI | 45 | Latest Price | $2.5700(1.58%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | HTBX declines -1.9% a day on average for past five trading days. | Weekly Trend | HTBX declines -3.2% a week on average for past two weeks. | Market Behavior | Growth stock rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) EEM(55%) VWO(54%) IPO(53%) BLOK(52%) DRIV(52%) | Factors Impacting HTBX price | HTBX will decline at least -2.245% in a week (0% probabilities). VIXM(-57%) VXX(-54%) UUP(-27%) EDOC(-10%) TBT(-9%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.245% (StdDev 4.49%) | Hourly BBV | 0.3 () | Intraday Trend | 6.6% | | | |
|
1 - 5 Day Possible Target | $-7.28(-383.27%) | Resistance Level | $2.74 | 5 Day Moving Average | $2.61(-1.53%) | 10 Day Moving Average | $2.71(-5.17%) | 20 Day Moving Average | $2.74(-6.2%) | To recent high | -43.4% | To recent low | 2.8% | Market Cap | $283m | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |